Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib plus individualized radiotherapy in locally advanced esophageal squamous cell carcinoma
ChiCTR2400086484Phase 2Not yet recruiting
- Sponsor
- Shuguang Hospital
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamiparib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shuguang Hospital. Primary endpoint: 1-year progression-free survival rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
pamiparib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400086484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086484.